Sign inJoin waitlistJoin the waitlist

Inhye Ahn

, Associate Director, Chronic Lymphocytic Leukemia Center · Mass General Brigham

Credentials: · · · · · ·

History

Mass General Brigham
Present

Hematology and Medical Oncology
Clinical Center at the National Institutes of Health
2013–2016
Internal Medicine
The Methodist Hospital
2010–2013
CATHOLIC UNIV, SEOUL
2004–2008

Research

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia
Blood · 2017 · First of 20 authors · 290 citations
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
Blood · 2020 · 267 citations
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study
Blood · 2018 · First of 24 authors · 168 citations

AW
Adrian Wiestner
32 papers
CS
Clare Sun
18 papers
Matthew Davids
15 papers
Jennifer Brown
13 papers
David Fisher
8 papers
Jennifer Crombie
8 papers
Philippe Armand
8 papers
Ann LaCasce
7 papers
Austin Kim
7 papers
Caron Jacobsen
7 papers
Constance Yuan
7 papers
Irina Maric
7 papers

Clinical trials

Mosunetuzumab for CLL MRD Clearance
Principal investigator · Recruiting · Phase 1, Phase 2
Inhye Ahn
2025–2032
Cardiotoxicities in Patients Receiving BTKi
Principal investigator · Withdrawn
Dana-Farber Cancer Institute
2024–2028
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
Principal investigator · Recruiting · Phase 2
Inhye Ahn
2024–2032
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
Principal investigator · Recruiting · Phase 2
Dana-Farber Cancer Institute
2022–2028